Search Results for: SPS Zertifizierungsprüfung 🅿 SPS Dumps ⌨ SPS Originale Fragen 👽 Öffnen Sie 《 www.itzert.com 》 geben Sie [ SPS ] ein und erhalten Sie den kostenlosen Download 🔪SPS Deutsch
Disease and Treatment Overview: Wild-Type Transthyretin Amyloidosis
Wild-type transthyretin amyloidosis (ATTRwt) is an age-related disease caused by transthyretin (TTR) proteins that become unstable, misfold, and build up in organs, impairing their function. It is a slowly progressive condition that affects older people, most often Caucasian men over 65 years of age. Heart disease is the hallmark of ATTRwt, but it is commonly preceded by other conditions, such as carpal tunnel syndrome or spinal stenosis.
Read More
About Amyloidosis
Read More
First treatment for AL Amyloidosis approved in US
Daratumumab has just been granted approval by the FDA for the treatment of AL Amyloidosis in the United States. Today marks a major milestone and an achievement that has been years in the making. Janssen applied for FDA approval for subcutaneous daratumumab (Darzalex Faspro) this summer for the treatment of AL Amyloidosis. It was previously approved for the treatment of multiple myeloma, and trials showed remarkable promise for its use in AL amyloidosis. The application is based on data from...
Read More
Managing GI Issues in Amyloidosis – FAQ
Dr. John Clarke from Stanford University presented in a recent ARC Talks webinar on Gastro Intestinal Disturbances and Symptom Relief for Amyloidosis. This report covers the most frequently asked questions and recommendations. (more…)
Read More
Coronavirus: What Amyloidosis Patients Should Know
COVID-19 has impacted everyone. Patients with amyloidosis may be at greater risk than the general population. In this frequently updated post, ARC provides the latest recommendations and resources. (more…)
Read More